Valuation
- Market cap
- 23,352,000
- Revenue TTM
- $0
- Net income TTM
- $-34,770,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 74,200
- Avg volume
- 58,740
- Day's range
- $2.17 – $2.38
- Shares out
- 9,979,000
- Stochastic %K
- 85%
- Beta
- 1.27
- Analysts
- Strong Sell
- Price target
- $17.25
Company profile
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other thera...
Show more
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 206 588 0256
- Website
- https://www.atossatherapeutics.com
- Address
- 448 NW Market Street, Suite 500, Seattle, United States
Latest news
No headlines yet.
